140 related articles for article (PubMed ID: 32907893)
21. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
[TBL] [Abstract][Full Text] [Related]
22. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
23. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
Ulivi P; Chiadini E; Dazzi C; Dubini A; Costantini M; Medri L; Puccetti M; Capelli L; Calistri D; Verlicchi A; Gamboni A; Papi M; Mariotti M; De Luigi N; Scarpi E; Bravaccini S; Turolla GM; Amadori D; Crinò L; Delmonte A
Clin Lung Cancer; 2016 Sep; 17(5):384-390. PubMed ID: 26712101
[TBL] [Abstract][Full Text] [Related]
24. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
[TBL] [Abstract][Full Text] [Related]
25. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
[TBL] [Abstract][Full Text] [Related]
26. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.
Ragusa M; Vannucci J; Ludovini V; Bianconi F; Treggiari S; Tofanetti FR; Flacco A; Colella R; Sidoni A; Crinò L; Puma F
Am J Clin Oncol; 2014 Aug; 37(4):343-9. PubMed ID: 23357969
[TBL] [Abstract][Full Text] [Related]
27. Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations.
Li M; Zhang L; Tang W; Duan JC; Jin YJ; Qi LL; Wu N
Cancer Imaging; 2019 Nov; 19(1):77. PubMed ID: 31783917
[TBL] [Abstract][Full Text] [Related]
28. Association of EGFR and KRAS mutations with expression of p-AKT, DR5 and DcR1 in non-small cell lung cancer.
Zhao XD; Deng HB; Lu CL; Bao YX; Lu X; Deng LL
Neoplasma; 2017; 64(2):182-191. PubMed ID: 28043144
[TBL] [Abstract][Full Text] [Related]
29. EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.
Créquit P; Ruppert AM; Rozensztajn N; Gounant V; Vieira T; Poulot V; Antoine M; Chouaid C; Wislez M; Cadranel J; Lavole A
Lung Cancer; 2016 Jun; 96():74-7. PubMed ID: 27133754
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population.
Fakhruddin N; Mahfouz R; Farhat F; Tfayli A; Abdelkhalik R; Jabbour M; Yehia L; Mahfoud Z; Zaatari G
Oncol Rep; 2014 Nov; 32(5):2223-9. PubMed ID: 25120214
[TBL] [Abstract][Full Text] [Related]
31. Construction of a reference material panel for detecting
Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
[TBL] [Abstract][Full Text] [Related]
32. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.
Pham D; Kris MG; Riely GJ; Sarkaria IS; McDonough T; Chuai S; Venkatraman ES; Miller VA; Ladanyi M; Pao W; Wilson RK; Singh B; Rusch VW
J Clin Oncol; 2006 Apr; 24(11):1700-4. PubMed ID: 16505411
[TBL] [Abstract][Full Text] [Related]
33. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
[TBL] [Abstract][Full Text] [Related]
34. Evaluating Real World Mutational Differences Between Hispanics and Asians in NSCLC at a Large Academic Institution in Los Angeles.
Hsu R; Herrmann A; Gaur K; Xia B; Nieva JJ
Clin Lung Cancer; 2022 Nov; 23(7):e443-e452. PubMed ID: 35902325
[TBL] [Abstract][Full Text] [Related]
35. Higher TP53 somatic mutation prevalence from liquid biopsy analysis in ever smoker non-small-cell lung cancer patients.
Erdem HB; Alay MT; Özdemir Z; Çevik E; Ateş Ö; Karaçin C; Şahin İ; Doğan M; Bahsi T
Mutat Res; 2024; 828():111847. PubMed ID: 38071953
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort.
Scoccianti C; Vesin A; Martel G; Olivier M; Brambilla E; Timsit JF; Tavecchio L; Brambilla C; Field JK; Hainaut P;
Eur Respir J; 2012 Jul; 40(1):177-84. PubMed ID: 22267755
[TBL] [Abstract][Full Text] [Related]
37. KRAS mutations in lung cancer.
Karachaliou N; Mayo C; Costa C; Magrí I; Gimenez-Capitan A; Molina-Vila MA; Rosell R
Clin Lung Cancer; 2013 May; 14(3):205-14. PubMed ID: 23122493
[TBL] [Abstract][Full Text] [Related]
38. The relationship between KRAS gene mutations and HLA class I antigen downregulation in the metastasis of non-small cell lung cancer.
He XP; Song FJ; Liu XY; Wang Z; Li XX; Liu FY; Chen G; Jiang WP
J Int Med Res; 2013 Oct; 41(5):1473-83. PubMed ID: 23975858
[TBL] [Abstract][Full Text] [Related]
39. Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer.
Wang X; Ricciuti B; Nguyen T; Li X; Rabin MS; Awad MM; Lin X; Johnson BE; Christiani DC
Cancer Res; 2021 May; 81(9):2566-2573. PubMed ID: 33653773
[TBL] [Abstract][Full Text] [Related]
40. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
